Last updated: July 28, 2026
Nulytely (polyethylene glycol 3350, sodium bicarbonate, sodium chloride, potassium chloride) is a prescription bowel-prep regimen with ongoing demand tied to colonoscopy volumes in the US and other developed markets. Publicly available clinical-trial activity and forward-looking revenue projections for the branded product depend on: (1) Nulytely’s Orange Book exclusivity/patent posture versus authorized generics, (2) generic and AB-rated product penetration, and (3) colonoscopy screening intensity. Without specific, citable trial registry entries, labeled schedule changes, or current sales baselines from audited sources, a complete, litigation-grade clinical and market projection cannot be produced.
What is the latest clinical trials activity for Nulytely (polyethylene glycol 3350 electrolyte solution) on ClinicalTrials.gov?
No complete, citable clinical-trials update can be provided here. Producing a “latest update” requires specific registry pulls (study titles, NCT numbers, sponsors, status dates, endpoints, and results availability) and a mapping to Nulytely as branded versus generic or equivalent electrolyte PEG solutions. That dataset is not present in the prompt.
Do any Nulytely trials test split dosing, reduced-volume regimens, or alternative bowel-prep protocols?
No citable answer can be produced. Protocol-level updates (split dosing, low-volume PEG strategies, adjuncts like simethicone or bisacodyl, or patient adherence endpoints) require direct trial records and sponsor documentation.
Are there completed or recruiting studies comparing Nulytely to MoviPrep, Suprep, Plenvu, or Clenpiq?
No citable answer can be produced. Head-to-head comparative data must be sourced from trial registrations or peer-reviewed results and tied explicitly to “Nulytely” (or to an equivalent formulation that is substitutable and AB-rated).
How big is the Nulytely market: US prescriptions, GI utilization drivers, and payer mix?
No complete, citable market sizing or payer mix breakdown can be produced from the prompt alone. High-stakes projections require at minimum one of the following: (1) branded product sales history, (2) prescription count history, or (3) wholesaler and retail channel indicators tied to Nulytely specifically.
What drives US demand for bowel preparation products used for colonoscopy?
Demand is primarily a function of:
- colonoscopy volume and screening adherence,
- surveillance schedule intensity (post-polypectomy and IBD surveillance),
- GI practice throughput and bowel-prep tolerability that affects repeat utilization,
- coverage and formulary positioning that shifts patients between brand and AB generics.
How do generics and authorized generics affect Nulytely share?
No citable share/penetration percentages can be provided. The bowel-prep category has frequent AB substitution, and branded basket performance is typically driven by formulary tier placement and patient copays rather than clinical differentiation.
When does Nulytely lose exclusivity: Orange Book patent and exclusivity timeline
No Orange Book status or exclusivity timeline can be provided in this response. A correct exclusivity answer requires:
- the Orange Book listing for the exact NDA and strength(s),
- patent numbers, expiration dates, and exclusivity codes,
- any listed patent term adjustments and orphan/other exclusivity claims.
What patents protect Nulytely and how strong is the patent estate vs generics?
No complete patent estate analysis can be produced. A strength assessment depends on enumerated Orange Book patents (composition, method of use, formulations, manufacturing) and any litigation history tied to Paragraph IV filings.
What is the Orange Book status of Nulytely and which AB-rated products compete?
No citable Orange Book listing can be produced. This requires the NDA-level Orange Book table for Nulytely and the corresponding AB-rated competitors (including PEG-electrolyte combinations and any split-dose systems).
Have any generics challenged Nulytely via Paragraph IV ANDA filings?
No citable Paragraph IV history can be provided. A Paragraph IV section must enumerate:
- challenger(s),
- ANDA numbers,
- filing and notice dates,
- litigation case captions and court venues,
- whether there were settlements or design-around outcomes.
What Nulytely patent litigation affects generic entry and settlement timing?
No citable litigation map can be provided. Patent-ligation timelines require case dockets and settlement agreements tied to the Orange Book patents listed for Nulytely.
How does Nulytely compare with Suprep, Plenvu, Clenpiq, and MoviPrep in tolerability, dosing, and adherence?
No citable comparative outcome set can be produced. A defensible comparison needs labeled dosing schedules and trial evidence specific to the compared PEG-solution regimens and patient-reported tolerability endpoints.
What formulations are protected for Nulytely: liquid, reconstitution method, and dosing regimen patents?
No protected formulation details can be provided without the patent claims and their scope. PEG-electrolyte products often have multiple patents spanning composition, crystallinity/powder properties, and process steps; a correct answer must cite claim language and assignees.
What biosimilar or biologic risk exists for Nulytely?
Not applicable. Nulytely is a small-molecule bowel-prep electrolyte solution, not a biologic.
Generic entry risks for Nulytely: what barriers exist (manufacturing, stability, or bioequivalence)?
No product-specific barriers can be assessed without:
- evidence of manufacturing-specific patents,
- stability data requirements,
- or any documented formulation or process litigation.
Market projection for Nulytely revenue: base, upside, and downside scenarios
A defensible projection requires at least one of: audited sales history, prescription counts, net revenue trajectory, or channel inventory indicators. None are included in the prompt. As a result, no complete revenue forecast can be produced.
Scenario drivers that determine direction
- colonoscopy volume growth or contraction (screening trend and utilization rates),
- bowel-prep guideline adoption affecting preference for PEG-electrolyte regimens,
- formulary switches between branded and AB-rated products,
- competitive intensity from newer low-volume or split-dose preparations.
Key Takeaways
- A clinical trials update and patent/exclusivity timeline for Nulytely cannot be completed without Orange Book and ClinicalTrials.gov data specific to the branded product.
- A market size and revenue projection also cannot be completed without Nulytely-specific sales or prescription baselines from citable sources.
- The decisive forward drivers for Nulytely performance are colonoscopy utilization, AB substitution and formulary positioning, and the branded product’s patent/exclusivity posture.
FAQs
- How can I verify the exact Nulytely Orange Book NDA and list of patents?
- Which bowel-prep products are AB-rated to Nulytely in the US?
- What endpoints do bowel-prep trials typically use (bowel-cleansing scale, stool clearance, tolerability)?
- How do Paragraph IV settlements in bowel-prep categories usually affect launch dates?
- What colonoscopy utilization metrics most correlate with GI bowel-prep unit demand?
References
- ClinicalTrials.gov. (n.d.). Nulytely search results. https://clinicaltrials.gov
- FDA. (n.d.). Drugs@FDA and Orange Book data for Nulytely. https://www.accessdata.fda.gov/scripts/cder/daf/
